Incyte Corp. Stock
Price
Target price
€91.14
€91.14
-0.220%
-0.2
-0.220%
€89.11
06.11.25 / Tradegate
WKN: 896133 / Symbol: INCY / Name: Incyte / Stock / Biotechnology & Medical Research / Large Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
The full analysis of the stock Incyte Corp. is only available for our menbers.
Not a member yet? Sign up for free!
Not a member yet? Sign up for free!
Financial data and news for Incyte
sharewise wants to provide you with the best news and tools for Incyte, so we directly link to the best financial data sources.
Financials
News
Can Incyte Deliver on 447% EPS Forecasts and Pipeline Hype?
During a year when healthcare stocks, especially biotechnology, have lagged so deeply behind the overall market, it’s particularly noteworthy that Incyte Corporation (NASDAQ: INCY) has managed to
Incyte Stock: FDA Approval Boosts Cancer Drug Portfolio
Incyte Corporation has secured a significant regulatory milestone as the US Food and Drug Administration approved Monjuvi for treating patients with relapsed or refractory follicular lymphoma. The
Incyte's (INCY) EVP and General Counsel Sold 4,100 Shares for $352,000
On October 2 and October 3, 2025, Sheila A. Denton, EVP & General Counsel of Incyte (NASDAQ:INCY), executed an option exercise and immediately sold 4,100 shares of common stock, as disclosed in this
